Background {#Sec1}
==========

Patients undergoing maintenance hemodialysis (MHD) exhibit accelerated atherosclerosis and are at high risk of developing cardiovascular events, even after controlling for traditional risk factors \[[@CR1]--[@CR3]\]. Certain non-traditional factors, such as oxidative stress and inflammation, have been implicated in the pathogenesis of atherosclerosis of end-stage renal disease (ESRD) \[[@CR4]\]. We and others have described that patients on MHD have increased markers of oxidative stress and inflammation, \[[@CR5]--[@CR7]\] which are worsened by loss of kidney function and to some extent with hemodialysis therapy.

Endothelial dysfunction is also commonly present in patients with ESRD and is associated with an increased risk of atherosclerotic events \[[@CR8]\]. Increased levels of asymmetric dimethylarginine (ADMA), a potent inhibitor of endothelial nitric oxide synthase, can contribute to endothelial dysfunction. ADMA levels correlate with atherosclerosis and predict morbidity and mortality in patients with ESRD \[[@CR9], [@CR10]\]. Arginine methylation occurs as a post-translational modification of proteins \[[@CR11]\]. After protein degradation, symmetric and asymmetric methylarginines are released and transported out of the cell through cationic amino-acid transporters \[[@CR12]\]. Elimination of symmetric dimethylarginine (SDMA) occurs primarily through glomerular filtration, whereas ADMA elimination depends on enzymatic degradation. Two enzymatic pathways are important in the elimination of ADMA: dimethyl-arginine dimethylamino-hydrolases (DDAH), enzymes expressed in brain, kidney and liver, the alanine glyoxylate aminotransferase 2 (AGXT2), a mitochondrial enzyme highly expressed in the kidney and liver \[[@CR13]--[@CR15]\]. Regardless of the mechanism of elimination, plasma levels of SDMA and ADMA are increased in patients with chronic kidney disease (CKD) and ESRD \[[@CR11], [@CR16]\].

ADMA may also impair endothelial function by activating the renin-angiotensin system \[[@CR17]\]. Conversely angiotensin II increases ADMA levels through activation of the NADPH oxidase \[[@CR18]\]. Previous studies have shown that treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduce ADMA levels in the general population \[[@CR19]--[@CR22]\]. To date, no study has compared the effects of ARBs or ACE inhibitors on ADMA levels in patients with ESRD. Based on studies in the general population, we hypothesized that short-term administration of either an ACE inhibitor or an ARB would lower ADMA levels in patients with ESRD undergoing MHD. We also hypothesized that these effects would be more noticeable during hemodialysis due to concurrent activation of the inflammatory response. In order to test this hypothesis, we measured ADMA levels in a three x three crossover, randomized double blind, placebo-controlled study designed to evaluate the effects of 1-week treatment of either ACE inhibitor or ARB.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

Details of the study have been previously described (NCT00732069, clinicaltrials.gov) \[[@CR5]\]. The study was approved by the Vanderbilt University Institutional Review Board. Briefly, adult subjects (18 years or older) with ESRD undergoing MHD (for at least 6 months) 3 times per week were included in the study. Patients were clinically stable with a pre-dialysis potassium levels less than 5.5 mmol/L and adequately dialyzed (kt/V \>1.2) with polysulphone membranes. Exclusion criteria for the study were the following: history of active connective tissue disease, acute infection within 1 month prior to the study, advanced liver disease, gastrointestinal dysfunction requiring parental nutrition or active malignancy, medications such as immunosuppressive drugs within 1 month prior to the study, use of anti-inflammatory medications other than aspirin less than 325 mg per day, use of vitamin E at a dose higher than 60 IU per day or vitamin C higher than 500 mg per day; history of myocardial infarction or cerebrovascular event within 3 months prior to the study, or ejection fraction lower than 40 %, pregnancy, breastfeeding, history of ACE inhibitor-associated angioedema, inability to discontinue ACE inhibitors or ARBs. Twenty patients participated in the study and signed informed consent. Fifteen patients completed the whole study. One subject voluntarily withdrew the study after being consented, and three participants were excluded due to exclusion criteria (uncontrollable hypertension, hypotension, and hyperkalemia). One subject was withdrawn from the study because of an event (cerebral ischemic stroke) that was not study related. Participants were recruited between October 2008 and January 2010; the study ended on March 2010. Further details of the study population have been published previously \[[@CR5]\]. Additional file [1](#MOESM1){ref-type="media"}: Figure S1 summarizes the patient enrollment process.

Study protocol {#Sec4}
--------------

The study was a three x three cross-over design, randomized, double-blind, placebo-controlled. Patients received ramipril (King Pharmaceutical, Bristol, TN), valsartan (Novartis Pharmaceutical, East Hanover, NJ) or placebo for 7 days. After a washout period of 3 weeks, patients received another treatment until every patient completed three treatment arms. The order of treatment was randomized using a three x three orthogonal Latin square design, as specified in Jones and Kenward \[[@CR23]\]. Treatment was dispensed by Vanderbilt Investigational Drug Services. Ramipril was administered for 2 days at 2.5 mg/d followed by 5 mg/d the following 5 days. Valsartan was given at 80 mg/d for 2 days, followed by 160 mg/d the following 5 days. On the seventh day of treatment, patients took the study medication early in the morning and arrived to the Clinical Research Center (CRC) at Vanderbilt University Medical Center for a regular session of hemodialysis. Blood samples were collected before the beginning of dialysis, 30 min, 1 h later, at the end of dialysis (4 h) and 2 h after the end of hemodialysis.

ADMA levels {#Sec5}
-----------

Blood samples were collected in tubes containing EDTA. After centrifugation, plasma was immediately collected and stored at −80 °C until processing for analysis. Levels of ADMA, SDMA, and arginine were measured by high performance liquid chromatography (HPLC) with fluorescence detection and using monomethyl-arginine as internal standard. Plasma samples were separated using solid-phase extraction, and analytes were derivatized with ortho-phthalaldehyde containing 3-mercaptopropionic acid, as previously described \[[@CR24]\]. Methylarginines levels were also measured in plasma obtained from participants in clinical trial NCT00607672 of subjects undergoing cardiac surgery, who were randomized to one week treatment with ramipril, candesartan or placebo prior to surgery.

### Markers of inflammation and oxidative stress {#Sec6}

Serum IL-6 concentrations were measured using Luminex immunoassay. Monocyte chemoattractant protein 1 levels were measured using a commercial kit (Linco Research, St. Charles, MO) according to the manufacturer instructions. Soluble CD40 ligand concentrations were measured in plasma using an ELISA kit (Quantikin, R&D Systems, Minneapolis, MN). We measured these inflammatory markers in our previous study \[[@CR5]\]. F2-isoprostanes, which is a stable and reliable marker of lipid peroxidation, were measured in plasma using ion gas-chromatophragy mass spectroscopy (GC/MS), as previously described \[[@CR25], [@CR26]\].

Cell culture {#Sec7}
------------

Human alveolar adenocarcinoma cells (A549) from passages four to six were used for the experiments. This cell line was used due to the constitutively expression of bradykinin receptors. Cells were cultured in DMEM medium supplemented with 10 % of fetal bovine serum at 37 °C. Cells were grown to confluence in 6-well plates and incubated in 2 ml of serum-free medium for 24 h. Cells were treated with vehicle, bradykinin (20 nM), bradykinin + the B2 receptor antagonist HOE-140 (1 μM), or bradykinin + the B1 receptor antagonist Lys (Des-Arg9-Leu8) bradykinin (1 μM). At the end of the treatment, culture medium was collected, centrifuged at 2500 g for 10 min, and stored at −80 °C. Cells were washed three times with PBS, scraped into PBS, and centrifuged for 5 min at 600xg. Cells were re-suspended in 250 μl of ice-cold sodium phosphate (100 mM, pH 6.5) and sonicated on ice. Cell lysate (220 μl) was mixed with 220 μl of perchloric acid (1.2 M), centrifuged at 2000 g for 10 min at 4 °C, and the supernatant collected and stored at −80 °C until further processing. Data was normalized by total protein content in the cells lysate and measured with the Pierce® BCA kit (Thermo Scientific, Rockford IL) according the manufacturer protocol.

Statistical analysis {#Sec8}
--------------------

Sample size was calculated based on the effect of treatment on IL-6 concentrations with 95 % power to detect a 30 % difference between ACEi and ARB. Data was presented as mean +/− standard error of the mean (SEM). A linear mixed effect model was used to compare the effect of treatment (ACEi, ARB, or placebo) during hemodialysis (time) on ADMA, SDMA, arginine and arginine to ADMA ratios. The model was selected based on the lower Akaike's information criteria. ADMA levels and arginine-to-ADMA ratios were correlated with markers of inflammation and oxidative using Spearman's rank correlation test. A two side *P* \< 0.05 was considered significant. Data analysis was performed using SPSS software (v. 20.0, IBM).

Results {#Sec9}
=======

Baseline patient demographics {#Sec10}
-----------------------------

Fifteen subjects were included in the study. Table [1](#Tab1){ref-type="table"} summarizes the demographic characteristic of the hemodialysis study participants. Causes of ESRD were diabetes mellitus (28 %, *n* = 4), hypertension (60 %, *n* = 9), non-steroidal anti-inflammatory drug (NSAID)-induced glomerulonephritis (6 %, *n* = 1), and unknown (6 %, *n* = 1).Table 1Baseline characteristicsParameterValueAge (yr)50.5 ± 3.1Gender (male:female)7:8Race (African-American: Caucasian: Hispanic)(11:2:2)Smoker (yes:no)(5:10)Hypertension (yes:no)15:0Previous ACEi or ARB use (yes:no)3:12BMI (kg/m^2^)30.2 ± 2.0Calcium x Phosphate product (mg^2^/dl^2^)53.3 ± 3.3Hemoglobin (g/dl)11.9 ± 0.3Erythropoietin dose (units)5111.1 ± 1488.4Heparin dose (units)4800 ± 579.0Data are presented as mean ± SEM

Effect of treatment on blood pressure and heart rate {#Sec11}
----------------------------------------------------

Systolic and diastolic blood pressure prior to the beginning of dialysis was not different among the treatment arms (Table [2](#Tab2){ref-type="table"}). Heart rate was also comparable among the treatment arms (Table [2](#Tab2){ref-type="table"}).Table 2Blood pressure and heart rate prior to the beginning of hemodialysisParameterPlaceboRamiprilValsartanSBP134.3 ± 7.4137.4 ± 7.4141.1 ± 1.7DBP77.0 ± 3.575.5 ± 3.774.4 ± 3.2Heart rate76.7 ± 4.175.5 ± 4.075.5 ± 3.7Data are presented as mean ± SEM

Effect of hemodialysis and treatment on methylarginines {#Sec12}
-------------------------------------------------------

ADMA and SDMA levels decreased by 30 min, reached a nadir at 1 h after the initiation of hemodialysis (Fig. [1](#Fig1){ref-type="fig"}), and remained lower at the end of hemodialysis (4 h). In contrast, SDMA reach the lowest level at the end of hemodialysis. Methylarginines levels increased 2 h after the end of hemodialysis but remained lower than baseline levels (14 and 27 % lower than baseline for ADMA and SDMA respectively). ADMA levels were significantly higher at baseline and throughout dialysis during ramipril treatment (Fig. [1](#Fig1){ref-type="fig"}) compared to treatment with either placebo or valsartan. Treatment with ramipril or valsartan did not affect SDMA levels.Fig. 1Effect of 1 week treatment with ramipril, valsartan and placebo on (**a**) asymmetric dimethylarginine (ADMA) and (**b**) symmetric dimethylarginine in patients with end-stage renal disease during hemodialysis

Effects of hemodialysis and treatment on arginine and arginine to ADMA ratio {#Sec13}
----------------------------------------------------------------------------

Arginine levels also decreased during hemodialysis, reaching the lowest level at the end of hemodialysis; 2 h later arginine levels returned to pre-dialysis levels (Fig. [2](#Fig2){ref-type="fig"}). Treatment with ramipril or valsartan did not affect arginine levels (Fig. [2](#Fig2){ref-type="fig"}). Arginine-to-ADMA ratios were lower in patients treated with ramipril at the beginning of hemodialysis and did not change during dialysis (Fig. [2](#Fig2){ref-type="fig"}). Conversely, treatment with either valsartan or placebo increased the arginine-to-ADMA ratio during hemodialysis.Fig. 2Effect of 1 week treatment with ramipril, valsartan and placebo on (**a**) arginine levels and (**b**) ratios of arginine- to-asymmetric dimethylarginine (ADMA) in patients with end-stage renal disease during hemodialysis

Correlation of ADMA with markers of inflammation and oxidative stress {#Sec14}
---------------------------------------------------------------------

ADMA levels correlated positively with markers of inflammation including interleukin-6 (IL-6; *ρ* = 0.23, *p* = 0.001), monocyte chemoattractant protein-1 (MCP-1; *ρ* = 0.27, *p* \< 0.001), and soluble CD 40 ligand (sCD40L; *ρ* = 0.22, *p* = 0.001). The arginine-to-ADMA ratio correlated negatively with the same markers of inflammation; IL-6 (*ρ* = −0.26, *p* \< 0.001), MCP-1 (*ρ* = −0.29, *p* \< 0.001), and sCD40L (*ρ* = −0.34, *p* \< 0.001). The ratio also correlated negatively with F2-Isoprostanes (*ρ* = −0.31, *p* \< 0.001), a marker of oxidative stress.

Effect of ramipril on methylarginines levels in patients with no history of ESRD {#Sec15}
--------------------------------------------------------------------------------

To evaluate if ramipril increases ADMA levels in patients with no history of ESRD, methylarginines levels were measured in subjects that were treated for 1 week with ramipril, candesartan, or placebo (NCT00607672) \[[@CR27]\]. Additional file [2](#MOESM2){ref-type="media"}: Table S1 summarizes the baseline demographic characteristics among the three treatment groups. One- week treatment with ramipril did not affect levels of ADMA, SDMA, or arginine (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Effect of 1 week treatment with ramipril, candesartan and placebo on (**a**) asymmetric dimethylarginine (ADMA), **b** symmetric dimethylarginine, **c** arginine levels, and (**d**) arginine-to-asymmetric dimethylarginine (ADMA) ratios in patients with no history of end-stage renal disease

Bradykinin increases ADMA level in human alveolar adenocarcinoma cells {#Sec16}
----------------------------------------------------------------------

ACE inhibitors, but not ARBs, increase bradykinin levels. Thus, we evaluated the effect of bradykinin on ADMA in human alveolar adenocarcinoma cells (A549), a cell line that expresses bradykinin receptors. A549 cells were incubated in the presence bradykinin and bradykinin receptors inhibitors. ADMA levels increased with incubation of bradykinin. Co-incubation with bradykinin B1 receptor inhibitor had no role in decreasing ADMA, whereas bradykinin B2 receptor inhibition reduced intracellular ADMA levels (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Effect of bradykinin (BK, 20nM) incubation on intracellular asymmetric dimethylarginine (ADMA) levels in human adenocarcinoma cell (A549). HOE stands for HOE-140, a bradykinin B2 receptor inhibitor (1 μM). Bradykinin B1 inhibition (B1 inh) was performed using the B1 receptor antagonist Lys (Des-Arg9-Leu8) BK (1 μM). Bars represent mean ± standard deviation

Discussion {#Sec17}
==========

This study examined the effects of ACE inhibitor and ARB on methylarginines in patients undergoing MHD. We found that short-term treatment with ramipril (1 week) increased ADMA levels and decreased the arginine-to-ADMA ratio compared to placebo and valsartan in patients undergoing MHD. Studies *in vitro* suggest that increase in ADMA production occur through stimulation of bradykinin B2 receptors.

ADMA levels are increased in patients undergoing MHD and correlate with all-cause mortality \[[@CR9]\]. In addition, ADMA levels correlate positively with markers of atherosclerosis such as carotid intima-media thickness, left ventricular hypertrophy, and cardiovascular events \[[@CR9], [@CR10], [@CR28], [@CR29]\]. Arginine and ADMA are substrate and inhibitor of endothelial nitric oxide synthase, respectively; thus the ratio of arginine to ADMA may modify the enzyme activity \[[@CR30]\]. Accordingly, a lower arginine to ADMA ratio has been also been associated with all-cause mortality and carotid intima-media thickness in the general population \[[@CR31]--[@CR33]\]. While the pathogenic role of ADMA in the cardiovascular disease is somewhat unclear, it has been shown to induce endothelial dysfunction, which is involved in the initiation and progression of atherosclerosis \[[@CR34]\]. Another possible factor that can contribute to increase cardiovascular risk is the over-activation of the sympathetic nervous system by ADMA. Experiments in humans have shown that nitric oxide inhibition results in the activation of the sympathetic nervous system \[[@CR35]\], a known risk factor cardiovascular disease. In fact, ADMA levels strongly correlates with norepinephrine levels in patients with ESRD \[[@CR36]\].

We did not find any effect of either ramipril or candersatan on ADMA levels in patients with preserved kidney function. But previous studies demonstrated that both ACE inhibitors and ARBs reduce ADMA levels in patients without kidney disease \[[@CR19]--[@CR22]\]. The duration of the treatment, one week *vs*. several weeks and months, may explain why neither ACE inhibitor nor ARB reduce ADMA levels in our study. Longer treatment with ACE inhibitors or ARBs may decrease ADMA by decreasing angiotensin II effects. Angiotensin II increases ADMA levels in smooth muscle cells by direct stimulation of AT1 receptors and by increasing oxidative stress \[[@CR18]\]. The latter is probably mediated through the production of reactive oxygen species by NADPH oxidase \[[@CR37], [@CR38]\]. Only one previous study in patients on MHD showed that 6-week treatment with valsartan or amlodipine reduced ADMA and SDMA \[[@CR39]\]. Findings from this study were attributed to a reduction in shear stress, which has been shown to increase ADMA release from endothelial cells \[[@CR40]\]. In comparison, we did not find reduction in ADMA after 1 week treatment with valsartan. Again, it is possible that a longer treatment with ARB may have an effect on ADMA levels. Nevertheless, our study is the first one to compare the effect of ACE inhibitors and ARBs on ADMA levels in patients on MHD.

In this study we found that ramipril, an ACE inhibitor, but not valsartan, an ARB, increased ADMA level. We found also that ramipril did not increase ADMA level in patients without ESRD, suggesting that other factors pertaining to ESRD, particularly hemodialysis may contribute to the ramipril-induced increase in ADMA levels. A potential explanation as to why ACE inhibitors and ARBs differ in their effect on ADMA levels could be that these medications also differ in their effect on the degradation of bradykinin. Specifically, ACE inhibitors increase bradykinin bioavailability, \[[@CR41]\] whereas ARBs does not. We have previously shown that ramipril treatment increased bradykinin levels during hemodialysis \[[@CR5]\]. Previous studies have shown that bradykinin increases reactive oxygen species production through stimulation of NADPH oxidases \[[@CR42]\]. NADPH activation increases ADMA levels by increasing protein methylation and inhibiting ADMA degradation, \[[@CR18], [@CR43]\] which are both mediated by reactive oxygen species. Thus, it is possible that ramipril increases ADMA levels by increasing bradykinin and oxidative stress. Our *in vitro* studies support this hypothesis. We found that bradykinin contributes to ADMA production in human adenocarcinoma cells. Importantly, we also found that incubation with the bradykinin B2 receptor antagonist HOE-140 reduces intracellular ADMA levels. Bradykinin B1 receptor blockage does not play a role in decreasing ADMA levels suggesting that bradykinin-dependent ADMA production occurs through bradykinin B2 receptor stimulation. A possible mechanism that has not been explored is the role of bradykinin on DDAH, the enzyme responsible for ADMA degradation. Bradykinin may increase ADMA levels by decreasing DDAH activity.

We also found that markers of inflammation positively correlate with ADMA levels and inversely with the arginine-to-ADMA ratio. The latter also has an inverse correlation with F2-Isoprostanes. These findings are in agreement with previous studies that showed the correlation between ADMA and inflammatory markers (C-reactive protein and IL-6) \[[@CR10], [@CR44]\]. We previously described that ramipril has a greater pro-inflammatory effect in patients with ESRD \[[@CR5]\]. Given the interrelation between ADMA and inflammation, it is not surprising that ACE inhibitors also increase ADMA levels in patients on MHD.

Our findings may some interesting implications. First and foremost, these data could explain the relative lack of efficacy of ACE inhibitors in improving cardiovascular outcomes in patients with ESRD, at least to some extent. To date, there are no clear-cut clinical guidelines for the use of ACE inhibitor or ARBs in patients with ESRD, mostly due to lack of randomized clinical trials. If anything, limited epidemiological data on this subject indicate that use of ACE inhibitor could be detrimental in patients with ESRD, at least when used in combination \[[@CR45]\]. Accordingly, further studies are necessary to examine the appropriate use of these potentially useful classes of cardiovascular medications. In addition, these data demonstrate that patients with ESRD, particularly ones on MHD behave differently in response to medications commonly used in the general populations. Accordingly, one should not simply assume that what has been observed in response to a medication in the general population can be safely extrapolated to patients with ESRD. Finally, our data once again highlight the importance of the so-called non-traditional cardiovascular risk factors in patients with ESRD. While this particular study focused on ACE inhibitors and ARBs, other interventions that modulate one or more of these metabolic derangements should be aggressively studied in patients with ESRD.

The strengths of the study are its design, a cross-over study that eliminates the within-subject variation, and the biological relevance of the findings. Study limitations include the short-duration of treatment (1 week) and a small sample size. It is notable that we nevertheless had sufficient statistical power to demonstrate significant differences. Finally, the levels of methylarginines are somewhat different from other published studies although there is a wide variability in terms of blood concentrations of ADMA and SDMA in ESRD patient population. In this study, we only used high-flux dialyzers, which may affect the removal of methylarginines. Although a previous study showed the type of dialyzer does not affect plasma ADMA removal, \[[@CR46]\] the choice of dialyzer could explain the differential pre-dialysis levels in methylarginines compared to other published studies \[[@CR9], [@CR10], [@CR47]\]. Nevertheless, use of same subjects as their own controls in this study should compensate for any difference on baseline level of methylarginines and the comparative effects of ACE inhibitor and ARB administered throughout the study.

Conclusions {#Sec18}
===========

In conclusion, we found that short-term ACE inhibitor and ARB administration differentially affects ADMA levels and the arginine-to-ADMA ratio in patients undergoing MHD. These parameters also correlate with markers of inflammation and oxidative stress. While these data suggest that ARB therapy may be a better treatment option for improving non-traditional cardiovascular risk factors in patients on MHD, further studies are required to determine the real therapeutic benefit of these interventions in order to reduce atherosclerotic burden in this patient population.

Additional files {#Sec19}
================

Additional file 1: Figure S1.CONSORT Flow Diagram. (DOCX 43 kb)Additional file 2: Table S1.Baseline characteristics of patients with no history of CKD. (DOCX 14 kb)
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